US 11,931,387 B2
Methods and compositions relating to microbial treatment and diagnosis of disorders
Colleen Cutcliffe, Menlo Park, CA (US); John S. Eid, San Francisco, CA (US); James H. Bullard, San Francisco, CA (US); and Marcus F. Schicklberger, Richmond, CA (US)
Assigned to Pendulum Therapeutics, Inc., San Francisco, CA (US)
Filed by Pendulum Therapeutics, Inc., San Francisco, CA (US)
Filed on Jul. 22, 2020, as Appl. No. 16/935,841.
Application 16/935,841 is a continuation of application No. 16/159,532, filed on Oct. 12, 2018, granted, now 10,842,830.
Application 16/159,532 is a continuation of application No. 15/271,672, filed on Sep. 21, 2016, granted, now 10,668,116, issued on Jun. 2, 2020.
Application 15/271,672 is a continuation of application No. 15/139,097, filed on Apr. 26, 2016, granted, now 9,486,487, issued on Nov. 8, 2016.
Application 15/139,097 is a continuation of application No. PCT/US2015/058511, filed on Oct. 30, 2015.
Claims priority of provisional application 62/073,912, filed on Oct. 31, 2014.
Prior Publication US 2020/0345796 A1, Nov. 5, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/745 (2015.01); A23L 33/135 (2016.01); A61K 9/00 (2006.01); A61K 9/28 (2006.01); A61K 9/48 (2006.01); A61K 31/00 (2006.01); A61K 31/733 (2006.01); A61K 35/74 (2015.01); A61K 35/741 (2015.01); A61K 35/742 (2015.01); A61K 45/06 (2006.01); C12N 1/20 (2006.01); C12Q 1/689 (2018.01); G01N 33/66 (2006.01); A61K 35/00 (2006.01)
CPC A61K 35/745 (2013.01) [A23L 33/135 (2016.08); A61K 9/0053 (2013.01); A61K 9/2846 (2013.01); A61K 9/48 (2013.01); A61K 9/4816 (2013.01); A61K 9/4891 (2013.01); A61K 31/00 (2013.01); A61K 31/733 (2013.01); A61K 35/74 (2013.01); A61K 35/741 (2013.01); A61K 35/742 (2013.01); A61K 45/06 (2013.01); C12N 1/20 (2013.01); C12Q 1/689 (2013.01); G01N 33/66 (2013.01); A23V 2002/00 (2013.01); A61K 2035/115 (2013.01); G01N 2333/605 (2013.01); G01N 2800/04 (2013.01)] 17 Claims
 
1. A composition comprising:
a microbe comprising a 16S rRNA sequence that has at least 97% sequence identity to a 16S rRNA sequence of Akkermansia muciniphila,
wherein the microbe is generated by growth on a plant-based culture medium.